Autolus Therapeutics (AUTL) News Today $1.94 -0.01 (-0.26%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Time to Buy?Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's What HappenedFebruary 20 at 11:53 AM | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Sees Large Increase in Short InterestAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 9,110,000 shares, a growth of 8.7% from the January 15th total of 8,380,000 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is presently 5.3 days.February 17, 2025 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Reaches New 52-Week Low - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low - What's Next?February 10, 2025 | marketbeat.comAutolus Therapeutics Will Remain Depressed For A WhileFebruary 5, 2025 | seekingalpha.comAutolus Therapeutics (NASDAQ:AUTL) Hits New 12-Month Low - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Hits New 1-Year Low - Should You Sell?February 4, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Short Interest Up 12.4% in JanuaryAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 8,630,000 shares, a growth of 12.4% from the December 31st total of 7,680,000 shares. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is currently 4.7 days.February 1, 2025 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Trading Down 4.6% - What's Next?Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.6% - Here's WhyJanuary 28, 2025 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's WhyAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Should You Buy?January 23, 2025 | marketbeat.comPerpetual Ltd Sells 319,632 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Perpetual Ltd lessened its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 20.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,279,620 shares of the company's stock aftJanuary 22, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Takes Position in Autolus Therapeutics plc (NASDAQ:AUTL)Hennion & Walsh Asset Management Inc. acquired a new stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 259,980 shares of the company's stock, vaJanuary 21, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Sees Large Growth in Short InterestAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 8,630,000 shares, an increase of 12.4% from the December 15th total of 7,680,000 shares. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is presently 4.7 days.January 18, 2025 | marketbeat.comJPMorgan Chase & Co. Has $4.66 Million Stake in Autolus Therapeutics plc (NASDAQ:AUTL)JPMorgan Chase & Co. grew its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 145.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,284,708 shares of the company's stock after purchasing anJanuary 18, 2025 | marketbeat.comAutolus Therapeutics presents clinical data updates at Tandem MeetingsJanuary 17, 2025 | markets.businessinsider.comAutolus presents new data on CAR-T therapy cost benefitsJanuary 17, 2025 | msn.comAutolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem MeetingsJanuary 17, 2025 | globenewswire.comAutolus Therapeutics (NASDAQ:AUTL) Shares Down 5.6% - Here's What HappenedAutolus Therapeutics (NASDAQ:AUTL) Shares Down 5.6% - Time to Sell?January 16, 2025 | marketbeat.comEuropean Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday TradingJanuary 15, 2025 | msn.comPositive Buy Rating for Autolus Therapeutics Driven by Aucatzyl’s Promising Launch and Strategic Growth ProspectsJanuary 14, 2025 | markets.businessinsider.comAutolus Therapeutics: Strategic Progress and Market Expansion Justify Buy RatingJanuary 14, 2025 | markets.businessinsider.comAutolus Therapeutics provides business updates, 2025 overviewJanuary 13, 2025 | msn.comAutolus Therapeutics (NASDAQ:AUTL) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday.January 13, 2025 | marketbeat.comAutolus Therapeutics Provides Business Updates and 2025 OverviewJanuary 13, 2025 | finance.yahoo.comAutolus Therapeutics (NASDAQ:AUTL) Shares Up 5% - Time to Buy?Autolus Therapeutics (NASDAQ:AUTL) Shares Up 5% - What's Next?December 31, 2024 | marketbeat.comWhy Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comAutolus Therapeutics plc (NASDAQ:AUTL) Short Interest UpdateAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 7,680,000 shares, an increase of 22.1% from the November 30th total of 6,290,000 shares. Based on an average daily trading volume, of 1,750,000 shares, the days-to-cover ratio is presently 4.4 days.December 29, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Sets New 52-Week Low - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Hits New 1-Year Low - Here's What HappenedDecember 25, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Here's What HappenedDecember 24, 2024 | marketbeat.comEuropean Equities Traded in the US as American Depositary Receipts Tumble in Friday Trading; Down 4.6% for WeekDecember 20, 2024 | msn.comAutolus Therapeutics (NASDAQ:AUTL) Hits New 12-Month Low - What's Next?Autolus Therapeutics (NASDAQ:AUTL) Hits New 1-Year Low - Here's What HappenedDecember 19, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Stock Price Down 4.4% - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.4% - Here's WhyDecember 18, 2024 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low - Here's WhyAutolus Therapeutics (NASDAQ:AUTL) Sets New 52-Week Low - Here's What HappenedDecember 13, 2024 | marketbeat.comWellington Management Group LLP Acquires 6,330,392 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Wellington Management Group LLP grew its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 35.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,220,226 shares of the company's stock after buying an addDecember 11, 2024 | marketbeat.comAutolus Therapeutics: Undervalued Potential in ALL Treatment with Obe-celDecember 9, 2024 | markets.businessinsider.comAutolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024December 9, 2024 | globenewswire.comFmr LLC Acquires 5,478,706 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Fmr LLC boosted its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 44.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,773,873 shares of the company's stock after aDecember 7, 2024 | marketbeat.comPositive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T TherapyDecember 5, 2024 | markets.businessinsider.comAutolus Therapeutics plc (AUTL): A Bull Case TheoryDecember 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday TradingDecember 4, 2024 | msn.comErste Asset Management GmbH Makes New $708,000 Investment in Autolus Therapeutics plc (NASDAQ:AUTL)Erste Asset Management GmbH purchased a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 195,000 shares of the company's stock, valued at approxDecember 4, 2024 | marketbeat.comAutolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of MedicineDecember 3, 2024 | markets.businessinsider.comAutolus Therapeutics announces publication of data from FELIX studyDecember 3, 2024 | markets.businessinsider.comGreat Point Partners LLC Has $10.21 Million Position in Autolus Therapeutics plc (NASDAQ:AUTL)Great Point Partners LLC decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 18.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,811,955 shares of the company's stock after sellingNovember 27, 2024 | marketbeat.comGoldman Sachs Upgrades Autolus Therapeutics plc - Depositary Receipt () (AUTL)November 19, 2024 | msn.comAutolus Therapeutics upgraded to Buy from Neutral at Goldman SachsNovember 18, 2024 | markets.businessinsider.comAutolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside AnticipatedNovember 18, 2024 | markets.businessinsider.comAutolus Therapeutics (NASDAQ:AUTL) Upgraded at The Goldman Sachs GroupThe Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $7.00 to $7.60 in a research report on Monday.November 18, 2024 | marketbeat.com298,086 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Acquired by GSA Capital Partners LLPGSA Capital Partners LLP bought a new position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 298,086 shares of the company's stock, valued at approximately $1,082,000November 16, 2024 | marketbeat.comRedburn Atlantic Upgrades Autolus Therapeutics plc - Depositary Receipt () (AUTL)November 16, 2024 | msn.comAutolus Therapeutics upgraded to Buy from Neutral at Redburn AtlanticNovember 15, 2024 | markets.businessinsider.comAutolus Therapeutics (NASDAQ:AUTL) Trading Up 4% - Still a Buy?Autolus Therapeutics (NASDAQ:AUTL) Trading 4% Higher - Should You Buy?November 15, 2024 | marketbeat.com Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Media Mentions By Week AUTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUTL News Sentiment▼1.520.60▲Average Medical News Sentiment AUTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUTL Articles This Week▼23▲AUTL Articles Average Week Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CG Oncology News Today Tarsus Pharmaceuticals News Today Janux Therapeutics News Today Agios Pharmaceuticals News Today NewAmsterdam Pharma News Today IDEAYA Biosciences News Today Schrödinger News Today Travere Therapeutics News Today Belite Bio News Today Vera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUTL) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUTL Stock Alerts